European Union Medical Device Directive (MDD) to Medical Device Regulations (MDR): strategic transition
This is especially important subject in medical device world. Understand strategic transition, one needs to go in detail as what is MDD with respect to MDR, why transition? And what transition?
MDD was labelled as directive, has quite relevant content
but was not sufficient in view of rapidly changing technology which could deliver
much advanced medical devices but also could have risk if it were regulated
just by MDD. Objective of new MDR in broad category was to bring, improved
consistency, better traceability, and transparency in regulatory process. Post
market performance became particularly important aspect to judge newly designed
advanced medical devices with modern technology.
It is especially important to note that MDR is regulation as
‘R’ of MDR stands for regulation and it is must to adopt. New deadline for MDR
compliance was 26th May 2021. Now it is on and all those who are
doing business of medical device in Europe has to see its compliance or else
there will be huge implication on business.
Let us see major changes in this transition from MDD to MDR.
1. Product
lifecycle approach like US FDA.
2. Device
re-classification. If your already existing device falls into other high
category of class, there will be tremendous implication on its management and
monitoring.
3. The
new updated Post Market Surveillance requirement.
4. General
safety and performance requirement.
5. Clinical Evaluation requirement (CER)
6. Introduction
of UDI (Unique device identification)
7. EUDAMED
(EU databank on medical devices)
All above requirements are not just one time activity but must
be covered under QMS and your existing QMS must be updated for risk management,
clinical investigation/evaluation and post market surveillance.
These changes implies to medical device industry in terms of
training of your all employees with new QMS and its execution so they can amend
documented system in QMS.
As said above if device class is changed to higher level as
per MDR reclassification, all requirements for new class then will be
applicable. This may involve additional cost of compliance and may involve prohibitive
cost to the same medical device which was already in market for long time at
lower cost. This is big business challenge. If this new class calls for new
clinical data, then it will be time consuming and costly too.
As the advancement in modern technology forced authority to transit
MDD to MDR, manufacturer should also look for modern technology in their
improvement too like in manufacturing, QMS. An automation is one of the best
approaches to avoid human error and faster solution for implementation so one
can be ready for both announced and unannounced audit.
Apart from transition steps mentioned above there are
several existing process steps also need relook.
Process may need re-design with the support of automation
for better consistency and no-defect. PMS process gains lot of importance so
attention must be given to that. Success of this depends on your improved risk
management process, product testing with new changed specification, gathering
new clinical evidence. Supply chain compliances with integrated approach to
have perfect traceability.
PSUR (periodic safety update report) is an important
activity required under PMS system and management must device system under
which this activity continues and meeting reviews, discusses and implements
CAPA.
1. Serious
incidents and field safety corrective actions from PMS.
2. Non
serious incidents and undesirable side effects.
3. Trend
data analysis.
4. Scientific
or technical literature review.
5. Feedback
and customer complaints.
6. Information
about similar medical devices.
There is another report needed by MDR called PMSR (Post
market surveillance report). Depending on class of your device one may need
either PSUR or PMSR.
Since PSUR report is very essential, following items are essential for PSUR report,
1. PMS
Data
2. Conclusion
of Benefit risk analysis
3. Description
of CAPA and rational or justification of the same.
4. Findings
of PMCF (Post market clinical follow up)
5. Device
sales volume and estimated user population.
6. Frequency
of device usage (if practical)
7. An
analysis and summary of all above listed items.
Similarly, PMS report is also needed to be regularly active
activity. All manufacturers should capture data actively, analyse them and make
results available to regulatory bodies.
Some companies offer software to manage all such activities
so one cannot miss any such time bound activities and reporting the same to
regulatory bodies.
Apart from above requirement it is obligatory on the part of
manufacturer to ensure that, health and safety of user is not compromised due
to defective, misleading, and dangerous products. When problem is detected,
company should immediately take actions of Recall if needed. Develop a solution
and keep users and regulatory body updated.
Comments
Post a Comment